文献速递膀胱癌与上尿路尿路上皮癌

试验设计驱动结局:BCG无应答原位癌试验疗效需统一

Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.
PubMed 文献 · BJU Int · 2026-09-25

该研究重建六项BCG无应答原位癌注册试验的生存数据,通过模拟分析评估活检时机、完全缓解评估、再治疗政策和退出处理对报告疗效的影响,发现再诱导再分类、假阴性率调整和评估时机统一会显著改变完全缓解率,提示不同药物的完全缓解率不可直接比较,未来试验应标准化活检时机并明确再治疗政策。

要点

  • 再诱导患者重新归类为非应答者后,NAI+BCG的12个月CR率从44%降至33%。
  • 调整11%假阴性率后,帕博利珠单抗12个月CR率降至17%(P=0.07)。
  • TAR-200在强制活检方案下12个月CR率为45%(P<0.01),优于分析参照。

核心结论

  • 试验设计人为因素显著影响BCG无应答原位癌研究报告的疗效,已发表的CR率在不同药物间不可直接比较。

研究设计与样本

  • 重建六项BCG无应答原位癌注册试验的生存数据并进行模拟分析,采用精确二项检验进行比较。

主要发现

  • 将再诱导患者重新归类为非应答者后,NAI+BCG的12个月CR率从44%降至33%,cretostimogene grenadenorepvec从45%降至38%。
  • 在缺乏强制活检的试验中调整11%假阴性率后,帕博利珠单抗12个月CR率降至17%(P=0.07),NAI考虑再诱导再分类后CR率为29%(P=0.4)。
  • TAR-200在强制活检方案下12个月CR率为45%(P<0.01),优于分析参照。

临床怎么用

  • 未来试验应标准化活检时机并明确再治疗政策,以确保跨研究比较有意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate how heterogeneity in response assessment protocols, including biopsy timing, complete response (CR) assessment, retreatment policies, and the handling of withdrawals, influences reported efficacy outcomes across single-arm registrational trials of patients with bacillus Calmette Guérin unresponsive (BCG-U) carcinoma in situ (CIS). PATIENTS AND METHODS: We reconstructed survival data from six registrational BCG-U CIS trials and conducted simulation analyses to test how trial design affects efficacy estimates. Specifically, we: (i) reclassified patients who underwent re-induction as non-responders; (ii) adjusted for false-negative rates of cystoscopy/cytology vs biopsy (as uniquely reported in the nadofaragene firadenovec trial, hence chosen as the analytical reference); (iii) harmonised CR assessment timing across trials. The exact binomial test was utilised for comparisons. RESULTS: Re-induction reclassification reduced the 12-month CR rate for nogapendekin alfa inbakicept (NAI) + BCG from 44% to 33% and for cretostimogene grenadenorepvec from 45% to 38%. After adjusting for an 11% false-negative rate in trials lacking mandatory biopsies, the pembrolizumab 12-month CR rate declined to 17% (P = 0.07), and NAI, accounting for re-induction reclassification, achieved a CR rate of 29% (P = 0.4). TAR-200 outperformed the analytical reference, with a 12-month CR rate of 45% under mandatory biopsy protocols (P < 0.01). CONCLUSIONS: Trial design artefacts significantly impact reported efficacy in BCG-U CIS studies. Published CR rates are not directly comparable across agents. Future trials should standardise biopsy timing and clearly define retreatment policies to ensure meaningful cross-study comparisons.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Robesti D, Kamat AM, Ploussard G, et al. Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials. BJU Int. 2026. PMID: 42798234. doi:10.1111/bju.70463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。